Stock Track | REMEGEN Soars 7.81% in Intraday Session as Vdisituzumab Nears Breakthrough Therapy Designation

Stock Track

01/05

REMEGEN (09995) surged 7.81% in the intraday session on Monday, driven by positive developments in its drug pipeline. The stock's rise follows the announcement that its drug Vdisituzumab is proposed to be included in the Breakthrough Therapy category for a new indication.

The proposed use is in combination with trastuzumab and toripalimab for the first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma with high HER2 expression. This marks the fourth potential Breakthrough Therapy designation for Vdisituzumab, highlighting its clinical significance.

Additionally, REMEGEN reported promising Phase I/II clinical study data for its PD-1/VEGF bispecific antibody, RC148. The data showed outstanding clinical efficacy and a manageable safety profile, further boosting investor confidence in the company's growth prospects.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1155356550"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1155356550\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1155356550?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-05 14:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155356550","market":"nz","top_or_hot":-1,"title":"Stock Track | REMEGEN Soars 7.81% in Intraday Session as Vdisituzumab Nears Breakthrough Therapy Designation","media":"Stock Track","content":"<p>REMEGEN (09995) surged 7.81% in the intraday session on Monday, driven by positive developments in its drug pipeline. The stock's rise follows the announcement that its drug Vdisituzumab is proposed to be included in the Breakthrough Therapy category for a new indication.</p><p>The proposed use is in combination with trastuzumab and toripalimab for the first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma with high HER2 expression. This marks the fourth potential Breakthrough Therapy designation for Vdisituzumab, highlighting its clinical significance.</p><p>Additionally, REMEGEN reported promising Phase I/II clinical study data for its PD-1/VEGF bispecific antibody, RC148. The data showed outstanding clinical efficacy and a manageable safety profile, further boosting investor confidence in the company's growth prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | REMEGEN Soars 7.81% in Intraday Session as Vdisituzumab Nears Breakthrough Therapy Designation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | REMEGEN Soars 7.81% in Intraday Session as Vdisituzumab Nears Breakthrough Therapy Designation\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-01-05 14:56</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>REMEGEN (09995) surged 7.81% in the intraday session on Monday, driven by positive developments in its drug pipeline. The stock's rise follows the announcement that its drug Vdisituzumab is proposed to be included in the Breakthrough Therapy category for a new indication.</p><p>The proposed use is in combination with trastuzumab and toripalimab for the first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma with high HER2 expression. This marks the fourth potential Breakthrough Therapy designation for Vdisituzumab, highlighting its clinical significance.</p><p>Additionally, REMEGEN reported promising Phase I/II clinical study data for its PD-1/VEGF bispecific antibody, RC148. The data showed outstanding clinical efficacy and a manageable safety profile, further boosting investor confidence in the company's growth prospects.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"榮昌生物","start_time":0,"source_url":"","article_id":"1155356550","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155356550","pubTimestamp":1767596202,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"REMEGEN (09995) surged 7.81% in the intraday session on Monday, driven by positive developments in its drug pipeline. The stock's rise follows the announcement that its drug Vdisituzumab is proposed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"个股追踪|瑞美根盘中大涨7.81%，因Vdisituzumab接近突破性疗法认定","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"REMEGEN (09995) surged 7.81% in the intraday session on Monday, driven by positive developments in its drug pipeline. The stock's rise follows the announcement that its drug Vdisituzumab is proposed to be included in the Breakthrough Therapy category for a new indication.The proposed use is in combination with trastuzumab and toripalimab for the first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma with high HER2 expression. This marks the fourth potential Breakthrough Therapy designation for Vdisituzumab, highlighting its clinical significance.Additionally, REMEGEN reported promising Phase I/II clinical study data for its PD-1/VEGF bispecific antibody, RC148. The data showed outstanding clinical efficacy and a manageable safety profile, further boosting investor confidence in the company's growth prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}